Shionogi and Co Ltd (4507) - Financial and Strategic SWOT Analysis Review

Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:


- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing and marketing of pharmaceutical products, diagnostic reagents and medical devices. The companys core pharmaceuticals product business offers drugs for the treatment of disorders in the areas of metabolism, infection, immunity and cancer pain. Shionogi also sells, distributes and provides information about diagnostic products in the fields of infectious diseases, cardiovascular diseases and allergies. The company operates a network of subsidiaries, branches, sales offices manufacturing plants and research laboratories across Japan, China, Taiwan in Asia; North America and Europe. Shionogi is headquartered in Osaka, Japan.

Shionogi & Co Ltd Key Recent Developments

Jun 24,2019: Shionogi agrees to license-out lusutrombopag
May 13,2019: Shionogi releases AMR Position Paper
Apr 01,2019: Shionogi announces the commencement of its operations of Shionogi Pharma
Mar 10,2019: Shionogi likely to shift its HQ to Netherlands
Feb 28,2019: Shionogi enters into comprehensive cooperation agreement in the field of infectious diesease focused on malaria with Nagasaki University

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 


Section 1 - About the Company
Shionogi & Co Ltd - Key Facts
Shionogi & Co Ltd - Key Employees
Shionogi & Co Ltd - Key Employee Biographies
Shionogi & Co Ltd - Major Products and Services
Shionogi & Co Ltd - History
Shionogi & Co Ltd - Company Statement
Shionogi & Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Shionogi & Co Ltd - Business Description
Shionogi & Co Ltd - Corporate Strategy
Shionogi & Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Shionogi & Co Ltd - Strengths
Shionogi & Co Ltd - Weaknesses
Shionogi & Co Ltd - Opportunities
Shionogi & Co Ltd - Threats
Shionogi & Co Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Shionogi & Co Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jun 24, 2019: Shionogi agrees to license-out lusutrombopag
May 13, 2019: Shionogi releases AMR Position Paper
Apr 01, 2019: Shionogi announces the commencement of its operations of Shionogi Pharma
Mar 10, 2019: Shionogi likely to shift its HQ to Netherlands
Feb 28, 2019: Shionogi enters into comprehensive cooperation agreement in the field of infectious diesease focused on malaria with Nagasaki University
Feb 19, 2019: SHIONOGI to announce corporate reorganization and personnel reassignment
Oct 29, 2018: Notice Regarding Reorganization of Manufacturing Subsidiaries through Company Split and Merger
Oct 18, 2018: Shionogi to announce corporate personnel reassignment
Oct 17, 2018: Shionogi established new manufacturing subsidiary in Japan
Oct 12, 2018: Shionogi Received “2018 Award for Excellence in Corporate Disclosure” from the Securities Analysts Association of Japan (SAAJ)
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Shionogi & Co Ltd, Key Facts
Shionogi & Co Ltd, Key Employees
Shionogi & Co Ltd, Key Employee Biographies
Shionogi & Co Ltd, Major Products and Services
Shionogi & Co Ltd, History
Shionogi & Co Ltd, Other Locations
Shionogi & Co Ltd, Subsidiaries
Shionogi & Co Ltd, Joint Venture
Shionogi & Co Ltd, Key Competitors
Shionogi & Co Ltd, Ratios based on current share price
Shionogi & Co Ltd, Annual Ratios
Shionogi & Co Ltd, Annual Ratios (Cont...1)
Shionogi & Co Ltd, Annual Ratios (Cont...2)
Shionogi & Co Ltd, Interim Ratios
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Shionogi & Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures


Shionogi & Co Ltd, Performance Chart (2015 - 2019)
Shionogi & Co Ltd, Ratio Charts
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
 


Shionogi Inc - Strategic SWOT Analysis Review

Shionogi Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on

USD 125 View Report

Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review

Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

USD 125 View Report

2024 Thailand Coagulation Testing Hemostasis Analyzers

2024 Thailand Coagulation Testing Hemostasis Analyzers and Reagents Market for Over 40 Hemostasis Tests: Supplier Strategies, Technology and Instrumentation Review This comprehensive report from is designed to help current

USD 2500 View Report

2024 Switzerland Coagulation Testing Market

2024 Switzerland Coagulation Testing Market--Hemostasis Analyzers and Consumables--2023 Supplier Shares, 2023-2028 Segment Volume and Sales Forecasts for over 40 Coagulation Assays, Opportunities for Suppliers--Molecular, Chromogenic and Immunodiagnostic Hemostasis Tests--Growth Strategies,

USD 2500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available